Nilotinib also suppressed proliferation in the estrogen-deprived breast cancer cell line MCF-7 [40], and metastatic melanoma cells expressing c-Abl/Arg kinase activity are also susceptible to nilotinib-mediated cell growth inhibition [41]. This evidence concerns the gene ABL1 and breast carcinoma.